Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 7, 2015, Pages 1258-1265

  Arnold, Staci D ^a   Jin, Zhezhen ^b   Sands, Stephen ^a   Bhatia, Monica ^a   Kung, Andrew L ^a   Satwani, Prakash ^a  

^a Department of Medicine   (United States)

^b Department of Medicine   (United States)

Author keywords

Cost; Outcomes; Pediatric; Quality of life; Sickle cell disease; Transplant

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PILOT STUDY; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SICKLE CELL ANEMIA; ADOLESCENT; ALLOTRANSPLANTATION; ANEMIA, SICKLE CELL; CASE CONTROL STUDY; CHRONIC DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; PATHOLOGY; PRESCHOOL CHILD; PSYCHOLOGY; QUALITY OF LIFE;

ADOLESCENT; ANEMIA, SICKLE CELL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; PILOT PROJECTS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84930575325     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.010     Document Type: Article

References (29)

1. Hassell K.L. Population estimates of sickle cell disease in the US. Am J Prev Med 2010, 38:S512-S521.
2. Mvundura M., Amendah D., Kavanagh P.L., et al. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer 2009, 53:642-646.
3. Amendah D.D., Mvundura M., Kavanagh P.L., et al. Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med 2010, 38(4 Suppl):S550-S556.
4. Kauf T.L., Coates T.D., Huazhi L., et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009, 84:323-327.
5. Powars D.R., Chan L.S., Hiti A., et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005, 84:363-376.
6. Lanzkron S., Haywood C., Segal J.B., Dover G.J. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006, 81:927-932.
7. Shenoy S. Has stem cell transplantation come of age in the treatment of sickle cell disease?. Bone Marrow Transplant 2007, 40:813-821.
8. Hsieh M.M., Fitzhugh C.D., Tisdale J.F. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 2011, 118:1197-1207.
9. Panepinto J.A., Walters M.C., Carreras J., et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007, 137:479-485.
10. Bhatia M., Jin Z., Baker C., et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 2014, 49:913-920.
11. Khera N., Zeliadt S.B., Lee S.J. Economics of hematopoietic cell transplantation. Blood 2012, 120:1545-1551.
12. Felder-Puig R., di Gallo A., Waldenmair M., et al. Health-related quality of life of pediatric patients receiving allogeneic stem cell or bone marrow transplantation: results of a longitudinal, multi-center study. Bone Marrow Transplant 2006, 38:119-126.
13. Kelly M.J., Pennarola B.W., Rodday A.M., Parsons S.K. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer 2012, 59:725-731. Journeys to Recovery Study H-CS.
14. Varni J.W., Seid M., Rode C.A. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999, 37:126-139.
15. Gusi N., et al. The EQ-5D health-related quality of life questionnaire. Handbook of disease burdens and quality of life measures 2010, Springer, New York.
16. Szende A., et al. EQ-5D value sets. Health Econ 2007, 14:21-28.
17. Manca A., Hawkins N., Sculpher M.J. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005, 14:487-496.
18. Hartman M., Martin A.B., Benson J., Catlin A. National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration. Health Aff (Millwood) 2013, 32:87-99. National Health Expenditure Accounts T.
19. Osborne R.H., De Abreu Lourenco R., Dalton A., et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007, 10:451-456.
20. Lin Y.F., Lairson D.R., Chan W., et al. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant 2010, 16:1272-1281.
21. Radhakrishnan K., Bhatia M., Geyer M.B., et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant 2013, 19:676-677.
22. Svahn B.M., Remberger M., Alvin O., et al. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant 2012, 47:706-715.
23. Dignan F.L., Potter M.N., Ethell M.E., et al. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Clin Transplant 2013, 27:E56-E63.
24. Kamani N.R., Walters M.C., Carter S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012, 18:1265-1272.
25. George B., Pati N., Gilroy N., et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010, 12:322-329.
26. Rustia E., Violago L., Jin Z., et al. Incidence of and risk factors for cytomegalovirus (CMV), Epstein Barr virus (EBV) and adenovirus (ADV) reactivation in pediatric recipients post allogeneic hematopoietic stem cell transplantation (alloHCT). Biol Blood Marrow Transplant 2014, 20:S84-S85.
27. Majhail N.S., Mothukuri J.M., Macmillan M.L., et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010, 54:138-143.
28. Bhatia M., Kolva E., Cimini L., et al. Health related quality of life following allogeneic hematopoietic stem cell transplantation for sickle cell disease. Pediatr Blood Cancer 2014, 61:S103.
29. van Agthoven M., Groot M.T., Verdonck L.F., et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002, 30:243-251.